<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="02/06/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9261367" creator="Noriko Katsu">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>9261367</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Inhibition of <term sem="Virus" id="T1" lex="human_immunodeficiency_virus_type_1">human immunodeficiency virus type 1</term> replication in vitro by a novel combination of <term sem="Protein_molecule" id="T2" lex="anti-Tat_single-chain_intrabodies">anti-Tat single-chain intrabodies</term> and <term sem="Organic_compound_other" id="T3" lex="NF-kappa_B_antagonist">NF-kappa B antagonists</term>.</sentence>
<event id="E1">
<type class="Negative_regulation" />
<theme idref="E2" />
<cause idref="T2" />
<cause idref="T3" />
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> human immunodeficiency virus type 1 replication in vitro <linkCause>by</linkCause> a novel <linkCause>combination of</linkCause> anti-Tat single-chain intrabodies and NF-kappa B antagonists.</clue>
</event>
<event id="E2">
<type class="Viral_life_cycle" />
<theme idref="T1" />
<clue>Inhibition of human immunodeficiency virus type 1 <clueType>replication</clueType> in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term sem="Protein_molecule" id="T4" lex="human_immunodeficiency_virus_type_1_(HIV-1)_Tat"><term sem="Virus" id="T5" lex="human_immunodeficiency_virus_type_1">Human immunodeficiency virus type 1</term> (HIV-1) <term sem="Protein_molecule" id="A1">Tat</term></term>, an early <term sem="Protein_family_or_group" id="T6" lex="regulatory_protein">regulatory protein</term> that is critical for <term sem="Other" id="T7"><term sem="DNA_domain_or_region" id="A14"><term sem="Virus" id="A2">viral</term> gene</term> expression</term> and <term sem="Other" id="T12">replication</term>, transactivates the <term sem="DNA_domain_or_region" id="T8" lex="HIV-1_long_terminal_repeat">HIV-1 long terminal repeat</term> (<term sem="DNA_domain_or_region" id="T9" lex="LTR">LTR</term>) via its binding to the <term sem="DNA_domain_or_region" id="T10" lex="transactivation_response_element">transactivation response element</term> (<term sem="DNA_domain_or_region" id="T11" lex="TAR">TAR</term>) and, along with <term sem="Protein_family_or_group" id="A8">other cellular factors</term>, increases <term sem="Other" id="A5">viral transcription</term> <frag id="F5"><term sem="Other" id="A6">initiation</term></frag> and <frag id="F6"><term sem="Other" id="A7">elongation</term></frag>.</sentence>
<event id="E3">
<type class="Positive_regulation" />
<theme idref="E43" />
<cause idref="A1" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is <clueType>critical</clueType> <linkTheme>for</linkTheme> viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E4">
<type class="Positive_regulation" />
<theme idref="E44" />
<cause idref="A1" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is <clueType>critical</clueType> <linkTheme>for</linkTheme> viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E43">
<type class="Gene_expression" />
<theme idref="A14" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene <clueType>expression</clueType> and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E44">
<type class="Viral_life_cycle" />
<theme idref="A2" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and <clueType>replication</clueType>, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E5">
<type class="Positive_regulation" />
<theme idref="T9" />
<cause idref="E6" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, <clueType>transactivates</clueType> the HIV-1 long terminal repeat (LTR) <linkCause>via</linkCause> its binding to the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E6">
<type class="Binding" />
<theme idref="A1" />
<theme idref="T11" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via <corefTheme>its</corefTheme> <clueType>binding</clueType> <linkTheme>to</linkTheme> the transactivation response element (TAR) and, along with other cellular factors, increases viral transcription initiation and elongation.</clue>
</event>
<event id="E7">
<type class="Positive_regulation" />
<theme idref1="A6" idref="A5" />
<cause idref="A1" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event id="E8">
<type class="Positive_regulation" />
<theme idref1="A7" idref="A5" />
<cause idref="A1" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event id="E9">
<type class="Positive_regulation" />
<theme idref1="A6" idref="A5" />
<cause idref="A8" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event id="E10">
<type class="Positive_regulation" />
<theme idref1="A7" idref="A5" />
<cause idref="A8" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, along with other cellular factors, <clueType>increases</clueType> viral transcription initiation and elongation.</clue>
</event>
<event id="E11">
<type class="Correlation" />
<theme idref="E7" />
<theme idref="E9" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, <linkTheme>along with</linkTheme> other cellular factors, increases viral transcription initiation and elongation.</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E40">
<type class="Correlation" />
<theme idref="E8" />
<theme idref="E10" />
<clue>Human immunodeficiency virus type 1 (HIV-1) Tat, an early regulatory protein that is critical for viral gene expression and replication, transactivates the HIV-1 long terminal repeat (LTR) via its binding to the transactivation response element (TAR) and, <linkTheme>along with</linkTheme> other cellular factors, increases viral transcription initiation and elongation.</clue>
<comment>NO CLUETYPE</comment>
</event>
<sentence id="S3"><term sem="Protein_molecule" id="A9">Tat</term> also superactivates the <term sem="DNA_domain_or_region" id="T13" lex="HIV-1_promoter"><term sem="Virus" id="T14" lex="HIV-1">HIV-1</term> promoter</term> through a <term sem="DNA_domain_or_region" id="T16" lex="TAR">TAR</term>-independent <term sem="Other" id="T15">mechanism</term>, including <cons sem="(AND Other Other)" id="T17" lex="(AND tumor_necrosis_factor_alpha-induced_activation protein_kinase_C_(PKC)-dependent_activation)"><frag id="F7"><term sem="Protein_molecule" id="A10">tumor necrosis factor alpha</term>-induced</frag> and <frag id="F8">protein kinase C (<term sem="Protein_molecule" id="T18" lex="PKC">PKC</term>)-dependent</frag> <frag id="F9">activation</frag></cons> of <term sem="Protein_complex" id="T19" lex="NF-kappa_B">NF-kappa B</term>, and <term sem="Organic_compound_other" id="A11">inhibitors</term> of <term sem="Protein_molecule" id="T20" lex="Tat">Tat</term> and <term sem="Protein_complex" id="T21" lex="NF-kappa_B">NF-kappa B</term> cooperatively down-regulate this <term sem="Protein_molecule" id="T23" lex="Tat">Tat</term>-mediated <term sem="Other" id="T22"><term sem="DNA_domain_or_region" id="T24" lex="LTR">LTR</term> superactivation</term>.</sentence>
<event id="E12">
<type class="Positive_regulation" />
<theme idref="T13" />
<cause idref="A9" />
<clue>Tat also <clueType>superactivates</clueType> the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event id="E13">
<type class="Positive_regulation" />
<theme idref="E12" />
<cause idref="E16" />
<clue>Tat also superactivates the HIV-1 promoter <linkCause>through</linkCause> a <corefCause>TAR-independent mechanism</corefCause>, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E15">
<type class="Positive_regulation" />
<theme idref="E12" />
<cause idref="E17" />
<clue>Tat also superactivates the HIV-1 promoter <linkCause>through</linkCause> a <corefCause>TAR-independent mechanism</corefCause>, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
<comment>NO CLUETYPE</comment>
</event>
<event assertion="non-exist" id="E14">
<type class="Regulation" />
<theme idref="E16" />
<cause idref="T16" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-<clueType>independent</clueType> mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event assertion="non-exist" id="E42">
<type class="Regulation" />
<theme idref="E17" />
<cause idref="T16" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-<clueType>independent</clueType> mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event id="E16">
<type class="Positive_regulation" />
<theme idref="T19" />
<cause idref="A10" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha<linkCause>-induced</linkCause> and protein kinase C (PKC)-dependent <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event id="E17">
<type class="Regulation" />
<theme idref="T19" />
<cause idref="T18" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)<linkCause>-dependent</linkCause> <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-mediated LTR superactivation.</clue>
</event>
<event id="E18">
<type class="Negative_regulation" />
<theme idref="E13" />
<cause idref1="T20" idref="A11" />
<cause idref1="T21" idref="A11" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B <clueType>cooperatively down-regulate</clueType> <corefTheme>this Tat-mediated LTR superactivation</corefTheme>.</clue>
</event>
<event id="E19">
<type class="Negative_regulation" />
<theme idref="E15" />
<cause idref1="T20" idref="A11" />
<cause idref1="T21" idref="A11" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B <clueType>cooperatively down-regulate</clueType> <corefTheme>this Tat-mediated LTR superactivation</corefTheme>.</clue>
</event>
<event id="E20">
<type class="Positive_regulation" />
<theme idref="T24" />
<cause idref="T23" />
<clue>Tat also superactivates the HIV-1 promoter through a TAR-independent mechanism, including tumor necrosis factor alpha-induced and protein kinase C (PKC)-dependent activation of NF-kappa B, and inhibitors of Tat and NF-kappa B cooperatively down-regulate this Tat-<linkCause>mediated</linkCause> LTR <clueType>superactivation</clueType>.</clue>
</event>
<sentence id="S4">In this study, a combined pharmacologic and genetic strategy using two <term sem="Protein_molecule" id="T25" lex="PKC">PKC</term> (<term sem="Protein_complex" id="T26" lex="NF-kappa_B">NF-kappa B</term>) inhibitors, <term sem="Organic_compound_other" id="T27" lex="pentoxifylline">pentoxifylline</term> (<term sem="Organic_compound_other" id="T28" lex="PTX">PTX</term>) and <term sem="Organic_compound_other" id="T29" lex="Go-6976">Go-6976</term>, and a stably expressed <term sem="Protein_molecule" id="T30" lex="anti-Tat_single-chain_intracellular_antibody">anti-<term sem="Protein_molecule" id="T31" lex="Tat">Tat</term> single-chain intracellular antibody</term> (<term sem="Protein_molecule" id="T32" lex="sFv_intrabody">sFv intrabody</term>) was employed to obtain cooperative inhibition of both <term sem="DNA_domain_or_region" id="A15"><term sem="Virus" id="T33" lex="HIV-1">HIV-1</term> <term sem="DNA_domain_or_region" id="T35" lex="LTR">LTR</term></term>-driven <term sem="Other" id="A12">gene expression</term> and <term sem="Other" id="T36" lex="HIV-1_replication"><term sem="Virus" id="T37" lex="HIV-1">HIV-1</term> replication</term>.</sentence>
<event uncertainty="probable" id="E21">
<type class="Negative_regulation" />
<theme idref="E22" />
<cause idref="T28" />
<cause idref="E26" />
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event uncertainty="probable" id="E24">
<type class="Negative_regulation" />
<theme idref="E22" />
<cause idref="T29" />
<cause idref="E26" />
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event uncertainty="probable" id="E27">
<type class="Negative_regulation" />
<theme idref="E25" />
<cause idref="T28" />
<cause idref="E26" />
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event uncertainty="probable" id="E28">
<type class="Negative_regulation" />
<theme idref="E25" />
<cause idref="T29" />
<cause idref="E26" />
<clue>In this study, a combined pharmacologic and genetic strategy using <corefCause>two PKC (NF-kappa B) inhibitors</corefCause>, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain <clueType>cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E22">
<type class="Positive_regulation" />
<theme idref="A12" />
<cause idref="A15" />
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-<clueType>driven</clueType> gene expression and HIV-1 replication.</clue>
<comment>NER: T34 del &quot;LTR-driven gene expression&quot;</comment>
</event>
<event id="E25">
<type class="Viral_life_cycle" />
<theme idref="T37" />
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably expressed anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 <clueType>replication</clueType>.</clue>
</event>
<event id="E26">
<type class="Gene_expression" />
<theme idref="T32" />
<clue>In this study, a combined pharmacologic and genetic strategy using two PKC (NF-kappa B) inhibitors, pentoxifylline (PTX) and Go-6976, and a stably <clueType>expressed</clueType> anti-Tat single-chain intracellular antibody (sFv intrabody) was employed to obtain cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<sentence id="S5">Treatment of cells with <term sem="Organic_compound_other" id="T38" lex="PTX">PTX</term> and <term sem="Organic_compound_other" id="T39" lex="Go-6976">Go-6976</term> resulted in cooperative inhibition of both <term sem="DNA_domain_or_region" id="T41" lex="HIV-1_LTR"><term sem="Virus" id="T42" lex="HIV-1">HIV-1</term> LTR</term>-driven <term sem="Other" id="A13">gene expression</term> and <term sem="Other" id="T43" lex="HIV-1_replication"><term sem="Virus" id="T44" lex="HIV-1">HIV-1</term> replication</term>.</sentence>
<event id="E29">
<type class="Negative_regulation" />
<theme idref="E31" />
<cause idref="T38" />
<cause idref="T39" />
<clue>Treatment of <clueLoc>cells</clueLoc> with PTX and Go-6976 <clueType>resulted in cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E30">
<type class="Negative_regulation" />
<theme idref="E33" />
<cause idref="T38" />
<cause idref="T39" />
<clue>Treatment of <clueLoc>cells</clueLoc> with PTX and Go-6976 <clueType>resulted in cooperative inhibition</clueType> <linkTheme>of</linkTheme> both HIV-1 LTR-driven gene expression and HIV-1 replication.</clue>
</event>
<event id="E31">
<type class="Positive_regulation" />
<theme idref="A13" />
<cause idref="T41" />
<clue>Treatment of cells with PTX and Go-6976 resulted in cooperative inhibition of both HIV-1 LTR-<clueType>driven</clueType> gene expression and HIV-1 replication.</clue>
</event>
<event id="E33">
<type class="Viral_life_cycle" />
<theme idref="T44" />
<clue>Treatment of cells with PTX and Go-6976 resulted in cooperative inhibition of both HIV-1 LTR-driven gene expression and HIV-1 <clueType>replication</clueType>.</clue>
</event>
<sentence id="S6">In addition, the combined use of <term sem="Protein_family_or_group" id="T45" lex="anti-Tat_sFv_intrabody">anti-<term sem="Protein_molecule" id="T46" lex="Tat">Tat</term> sFv intrabodies</term> and the two <term sem="Organic_compound_other" id="T47" lex="NF-kappa_B_inhibitor"><term sem="Protein_complex" id="T48" lex="NF-kappa_B">NF-kappa B</term> inhibitors</term> retained the virus in the latent state for as long as 45 days.</sentence>
<event id="E34">
<type class="Negative_regulation" />
<theme idref="T42" />
<cause idref="T45" />
<cause idref="T38" />
<cause idref="T39" />
<clue>In addition, the combined use of anti-Tat sFv intrabodies and the <corefCause>two NF-kappa B inhibitors</corefCause> <clueType>retained</clueType> <corefTheme>the virus</corefTheme> <clueType>in the latent state</clueType> <clueTime>for as long as 45 days</clueTime>.</clue>
<comment>CAUTION: three CAUSEs in combination</comment>
</event>
<sentence id="S7">The combined treatment resulted in more durable inhibition of <term sem="Other" id="T49" lex="HIV-1_replication"><term sem="Virus" id="T50" lex="HIV-1">HIV-1</term> replication</term> than was seen with the <term sem="Organic_compound_other" id="T51" lex="NF-kappa_B_inhibitor"><term sem="Protein_complex" id="T52" lex="NF-kappa_B">NF-kappa B</term> inhibitors</term> alone or the anti-<term sem="Protein_family_or_group" id="T53" lex="Tat_sFv_intrabody"><term sem="Protein_molecule" id="T54" lex="Tat">Tat</term> sFv intrabodies</term> alone.</sentence>
<event id="E35">
<type class="Negative_regulation" />
<theme idref="E36" />
<cause idref="T45" />
<cause idref="T38" />
<cause idref="T39" />
<clue><corefCause>The combined treatment</corefCause> <clueType>resulted in</clueType> more durable <clueType>inhibition</clueType> <linkTheme>of</linkTheme> HIV-1 replication than was seen with the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
</event>
<event id="E36">
<type class="Viral_life_cycle" />
<theme idref="T50" />
<clue>The combined treatment resulted in more durable inhibition of HIV-1 <clueType>replication</clueType> than was seen with the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
</event>
<event id="E37">
<type class="Positive_regulation" />
<theme idref="E36" />
<cause idref="T51" />
<clue>The combined treatment resulted in more durable inhibition of HIV-1 replication than was seen <linkCause>with</linkCause> the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
<comment>NO CLUETYPE</comment>
</event>
<event id="E38">
<type class="Positive_regulation" />
<theme idref="E36" />
<cause idref="T53" />
<clue>The combined treatment resulted in more durable inhibition of HIV-1 replication than was seen <linkCause>with</linkCause> the NF-kappa B inhibitors alone or the anti-Tat sFv intrabodies alone.</clue>
<comment>NO CLUETYPE</comment>
</event>
<sentence id="S8">Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like the one reported here may improve the survival of <term sem="Cell_cultured" id="T55" lex="transduced_cell">transduced cells</term> and prolong clinical benefit.</sentence>
<event uncertainty="probable" id="E39">
<type class="Positive_regulation" />
<theme idref="E41" />
<cause idref="E35" />
<clue>Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like <corefCause>the one</corefCause> reported here may <clueType>improve</clueType> the survival <linkTheme>of</linkTheme> transduced cells and prolong clinical benefit.</clue>
</event>
<event id="E41">
<type class="Physiological_process" />
<theme idref="T55" />
<clue>Together, these results suggest that in future clinical gene therapy trials, a combined pharmacologic and genetic strategy like the one reported here may improve the <clueType>survival</clueType> <linkTheme>of</linkTheme> transduced cells and prolong clinical benefit.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
